The somatic activating janus kinase 2 mutation
Posted by kinsxu on Monday, November 21, 2011
The somatic activating janus kinase 2 mutation (JAK2)V617F is
detectable in most patients with polycythemia vera (PV). Here we report
that CP-690550 exerts greater antiproliferative and pro-apoptotic
activity against cells harboring JAK2V617F compared with JAK2WT.
CP-690550 treatment of murine factor-dependent cell
Patersen–erythropoietin receptor (FDCP-EpoR) cells harboring human
wild-type or V617F JAK2 resulted in inhibition of cell proliferation
with a 50% inhibitory concentration (IC50) of 2.1 µM and
0.25 µM, respectively. Moreover, CP-690550 induced a significant
pro-apoptotic effect on murine FDCP-EpoR cells carrying JAK2V617F,
whereas a lesser effect was observed for cells carrying wild-type JAK2.
This activity was coupled with inhibition of phosphorylation of the key
JAK2V617F-dependent downstream signaling effectors signal
transducer and activator of transcription (STAT)3, STAT5, and v-akt
murine thymoma viral oncogene homolog (AKT). Furthermore, CP-690550
treatment of ex-vivo-expanded erythroid progenitors from JAK2V617F-positive PV patients resulted in specific, antiproliferative (IC50 = 0.2 µM)
and pro-apoptotic activity. In contrast, expanded progenitors from
healthy controls were less sensitive to CP-690550 in proliferation (IC50 > 1.0 µM),
and apoptosis assays. The antiproliferative effect on expanded patient
progenitors was paralleled by a decrease in JAK2V617F mutant allele frequency, particularly in a patient homozygous for JAK2V617F.
Flow cytometric analysis of expanded PV progenitor cells treated with
CP-690550 suggests a possible transition towards a pattern of erythroid
differentiation resembling expanded cells from normal healthy controls.
(Cancer Sci 2008; 99: 1265–1273)